Doxazosin Tablet
Product Images NDC 59651-892

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 59651-892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 3 (Doxazosin Fig1)

This text provides data from three different studies evaluating the effects of doxazosin on maximum flow rate and symptom score in patients with benign prostatic hyperplasia (BPH). The studies involved titration to maximum or fixed doses of doxazosin over varying time periods. The results include changes in maximum flow rate (measured in mL/sec) and symptom scores based on different questionnaires. Study 2 specifically highlights the maximum flow rate and symptom score outcomes for patients receiving placebo, 4mg doxazosin, and 8mg doxazosin. The text also mentions the sample sizes and statistical significance of the results compared to placebo.*

FDA Label Image

Figue 1 (Doxazosin Fig2)

This text provides data on the mean change in total symptom score and mean increase in maximum urinary flow rate from baseline for a study involving doxazosin treatment over a specific duration in weeks. The study had a sample size of 47 for the symptom score analysis and 50 for the flow rate analysis. The results are shown graphically over the treatment timeline.*

FDA Label Image

Package Label-principal Display Panel (1 mg (100 Tablet Bottle))

This text provides information about a medication called Doxazosin Tablets, USP. Each tablet contains doxazosin mesylate equivalent to 1 mg of doxazosin as a free base. The medication is distributed by Aurobindo Pharma USA, Inc. and should be stored in a tight, light-resistant container. It is essential to keep the medication out of reach of children and store it at 20° to 25°C (68° to 77°F). The text also mentions that the usual dosage information can be found in the accompanying prescribing information. Additionally, the packaging will include a GTIN, Serial Number, Expiry Date, and LOT that will be human-readable along with a 2D coding area.*

FDA Label Image

Package Label-principal Display Panel (2 mg (100 Tablet Bottle))

FDA Label Image

Package Label-principal Display Panel (4 mg (100 Tablet Bottle))

This text provides information about a medication containing doxazosin mesylate in tablet form, each tablet equivalent to 4 mg of doxazosin. The tablets are distributed by Aurobindo Pharma USA, Inc. and are meant to be dispensed in a tight, light-resistant container. The storage instructions recommend keeping the container tightly closed, storing at a temperature between 20°C to 25°C, and keeping the medication out of reach of children. The text also mentions the production in India and includes a code for tracking. Additionally, guidelines for printing certain information on the packaging are provided.*

FDA Label Image

Package Label-principal Display Panel (8 mg (100 Tablet Bottle))

FDA Label Image

Chemical Structure (Doxazosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.